CCL25



CCL25

Q1QQ1G2GG2V3VV3F4FF4E5EE5D6DD6C7CC7C8CC8L9LL9A10AA10Y11YY11H12HH12Y13YY13P14PP14I15II15G16GG16W17WW17A18AA18V19VV19L20LL20R21RR21R22RR22A23AA23W24WW24T25TT25Y26YY26R27RR27I28II28Q29QQ29E30EE30V31VV31S32SS32G33GG33S34SS34C35CC35N36NN36L37LL37P38PP38A39AA39A40AA40I41II41F42FF42Y43YY43L44LL44P45PP45K46KK46R47RR47... and 80 more residue(s)...... and 80 more residue(s)

SMILES None
InChIKey None
Sequence QGVFEDCCLAYHYPIGWAVLRRAWTYRIQEVSGSCNLPAAIFYLPKRHRKVCGNPKSREVQRAMKLLDARNKVFAKLHHNTQTFQAGPHAVKKLSSGNSKLSSSKFSNPISSSKRNVSLLISANSGL

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections



Bioactivities

CCL25

Q1QQ1G2GG2V3VV3F4FF4E5EE5D6DD6C7CC7C8CC8L9LL9A10AA10Y11YY11H12HH12Y13YY13P14PP14I15II15G16GG16W17WW17A18AA18V19VV19L20LL20R21RR21R22RR22A23AA23W24WW24T25TT25Y26YY26R27RR27I28II28Q29QQ29E30EE30V31VV31S32SS32G33GG33S34SS34C35CC35N36NN36L37LL37P38PP38A39AA39A40AA40I41II41F42FF42Y43YY43L44LL44P45PP45K46KK46R47RR47... and 80 more residue(s)...... and 80 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections



Compound is not listed as a drug.